The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population

Journal of Human Hypertension

Volumn 11, Issue SUPPL. 2, 1997, Pages

  McInnes, G T ^a   O'Kane, K P J ^a   Jonker, J ^b   Roth, J ^c  

^a WESTERN INFIRMARY   (United Kingdom)

^b Stichting Romeres   (Netherlands)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Angiotensin AT1 receptor blocker; Candesartan cilexetil; Clinical study; Elderly patients; Hypertension

Indexed keywords

CANDESARTAN HEXETIL; PLACEBO;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESSENTIAL HYPERTENSION; FEMALE; GERIATRIC PATIENT; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; VERTIGO;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; PATIENT COMPLIANCE; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0030707643     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Fifth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-183.
2. Bennett NC. Hypertension in the elderly. Lancet 1994; 344: 442-449.
3. Rose G. Strategy of prevention: lessens from cardiovascular disease. Br Med J 1981; 262: 1847-1851.
4. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994; 50: 272-298.
5. Tjoa HI, Kaplan NM. Treatment of hypertension in the elderly. JAMA 1990; 264: 1015-1018.
6. Weber MA, Neutal JM, Cheung DG. Hypertension in the aged: a pathophysiologic basis for treatment. Am J Cardiol 1989; 63: 25H-32H.
7. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
8. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor inhibition. A new therapeutic principle. Arch Intern Med 1996; 156: 1957-1965.
9. Bauer JH, Reams GP. The angiotensin II type I receptor antagonists. A new class of antihypertensive drugs. Arch Intern Med 1995; 155: 1361-1368.
10. Lacourcière Y et al. Effects of modulators of the reninangiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387-1393.
11. 1 receptor. Eur J Pharmacol 1997; 319: 137-146.
12. Delzcrétaz E et al. Characterisation of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 251: 14-21.
13. 1-(IH-tetrazol-5-yl) biphenyl-4-yl] methyl]-IH-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′- (IH-tetrazol-5-yl) biphenyl-4-yl] methyl]-IH-benzimidazole-7-carboxylate (TCV-116) J Pharmacol Exp Ther 1993; 266: 114-120.
14. Brunner HR et al. Angiotensin II antagonists DuP 753 and TCV-116. J Hypertens 1994; 12 (Suppl 9): S29-S34.
15. Chan JCN et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens 1995; 9: 765-771.
16. Dahlöf B et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-582.
17. MacKay JH et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-285.
18. Tikkanen I, Omvik P, Jensen AE. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-1351.
19. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 (Suppl 2): S49-S53.
20. O'Kane KPJ, Fridman K, McInnes G. Tolerability and efficacy of candesartan cilexetil 32 mg once daily in hypertensive patients. American Society of Hypertension 1997; abstract.
21. Farsang C et al. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination. Am J Hypertens 1997; 10 (4 Pt 2): 80A
22. Fletcher AE, Dollery CT. Side effects associated with inhibitors of angiotensin-converting enzyme. In: Robertson JIS, Nicholls MG (eds). The Renin-Angiotensin system. Gower Medical Publishing: London, 1993, pp 99.1-99.4.
23. Tuck M, Janssens M. The differential antihypertensive efficacy of antihypertensive agents in the elderly. J Hum Hypertens 1990; 4: 415-420.
24. Nagano M, Higaki J, Mikami H, Ogihara T. Role of the renin-angiotensin system in hypertension in the elderly. Blood Pressure 1994; 3 (Suppl 5): 130-133.
25. Fyhrquist F et al. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989; 226: 257-260.
26. Shand BI et al. Effects of losartan on haematology and haemorrheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233-235.
27. Trenkwalder P, Lehtovirta M, Dahl K. Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes. J Hum Hypertens 1997; 11 (Suppl 2): S81-S83.